Teleconferência de Resultados do 2T26 da Annexon (ANNX): ARCHER II Expandido, Submissão do BLA Dentro do Previsto
A teleconferência de resultados do 2º trimestre de 2026 da Annexon abordou o novo desfecho de 24 meses do ARCHER II, os dados iniciais do FORWARD e a submissão planejada de BLA do tanruprubart no 4º trimestre.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.